@article{ETD,
      recid = {357},
      author = {Friedman, Kevin},
      title = {Augmenting the effector phase of adoptive T cell  immunotherapy of cancer},
      publisher = {Oregon Health and Science University},
      school = {Ph.D.},
      address = {2009},
      number = {ETD},
      abstract = {Adoptive T cell immunotherapy has shown significant  promise in advanced melanoma, with over half of patients  who failed standard treatments achieving objective clinical  responses after receiving tumor‑specific T cells following  nonmyeloablative lymphopenic conditioning. This work  examines the T cell populations and molecular mechanisms  that enhance anti‑tumor efficacy in this setting. We  demonstrate that durable, potent anti‑tumor responses  require the presence of both tumor‑specific CD4⁺ and CD8⁺ T  cells in the lymphopenic host. Additionally, we show that T  cells deficient in the ubiquitin‑specific protease Ubp43  exhibit superior therapeutic activity compared to wild‑type  cells. These findings highlight key cellular components  essential for effective adoptive T cell therapy and suggest  a strategy to improve clinical outcomes by targeting  Ubp43.},
      url = {http://digitalcollections.ohsu.edu/record/357},
      doi = {https://doi.org/10.6083/M4QV3JHF},
}